MARKSANS — Marksans Pharma Balance Sheet
0.000.00%
- IN₹87.21bn
- IN₹83.57bn
- IN₹26.23bn
- 63
- 17
- 28
- 24
Annual balance sheet for Marksans Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,094 | 3,467 | 7,151 | 7,003 | 7,046 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,714 | 3,978 | 4,195 | 4,591 | 6,093 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9,023 | 12,012 | 16,753 | 18,625 | 22,041 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,540 | 3,423 | 3,869 | 6,811 | 8,954 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 12,283 | 16,401 | 21,904 | 26,810 | 32,396 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,984 | 3,562 | 3,410 | 3,898 | 4,773 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3,418 | 4,378 | 4,452 | 6,159 | 7,727 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 8,865 | 12,023 | 17,452 | 20,651 | 24,669 |
| Total Liabilities & Shareholders' Equity | 12,283 | 16,401 | 21,904 | 26,810 | 32,396 |
| Total Common Shares Outstanding |